千红制药：创新药项目按计划推进临床试验

证券之星2025-09-22

证券之星消息，千红制药(002550)09月22日在投资者关系平台上答复投资者关心的问题。

投资者提问：董秘请问:公司这段时间的股价是不是预期两个创新药临床试验进程基本上不可能达成你所说拨云见天是吗？

千红制药回复：尊敬的投资者，您好，公司创新药项目QHRD106、QHRD107等均按计划有序推进临床试验，目前正处于与监管部门积极沟通申请下一阶段临床研究的过程中。股价波动受多重因素影响，公司将持续关注国家创新药政策导向，全力推进创新药研发进程。具体进展请关注公司后续公告，感谢您对公司的关注。

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2569099812?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-22 15:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569099812","market":"fut","top_or_hot":-1,"title":"千红制药：创新药项目按计划推进临床试验","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/002550\">千红制药</a>(002550)09月22日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：董秘请问:公司这段时间的股价是不是预期两个创新药临床试验进程基本上不可能达成你所说拨云见天是吗？</p><p>千红制药回复：尊敬的投资者，您好，公司创新药项目QHRD106、QHRD107等均按计划有序推进临床试验，目前正处于与监管部门积极沟通申请下一阶段临床研究的过程中。股价波动受多重因素影响，公司将持续关注国家创新药政策导向，全力推进创新药研发进程。具体进展请关注公司后续公告，感谢您对公司的关注。</p><p>以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>千红制药：创新药项目按计划推进临床试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n千红制药：创新药项目按计划推进临床试验\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-22 15:07 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2025092200014036.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，千红制药(002550)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘请问:公司这段时间的股价是不是预期两个创新药临床试验进程基本上不可能达成你所说拨云见天是吗？千红制药回复：尊敬的投资者，您好，公司创新药项目QHRD106、QHRD107等均按计划有序推进临床试验，目前正处于与监管部门积极沟通申请下一阶段临床研究的过程中。股价波动受多重因素影响，公司将持续关注...</p>\n\n<a href=\"https://stock.stockstar.com/RB2025092200014036.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0239","symbol_name":"医药制造","start_time":0,"source_url":"https://stock.stockstar.com/RB2025092200014036.shtml","article_id":"2569099812","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569099812","pubTimestamp":1758524837,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，千红制药09月22日在投资者关系平台上答复投资者关心的问题。千红制药回复：尊敬的投资者，您好，公司创新药项目QHRD106、QHRD107等均按计划有序推进临床试验，目前正处于与监管部门积极沟通申请下一阶段临床研究的过程中。股价波动受多重因素影响，公司将持续关注国家创新药政策导向，全力推进创新药研发进程。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","BK0239":"医药制造","BK1161":"生物科技","06978":"永泰生物-B","BK1574":"生物医药B类股","002550":"千红制药"},"translate_title":"Qianhong Pharmaceutical: Innovative drug projects advance clinical trials as planned","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"06978":1.5,"002550":1.5},"content_text":"证券之星消息，千红制药(002550)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘请问:公司这段时间的股价是不是预期两个创新药临床试验进程基本上不可能达成你所说拨云见天是吗？千红制药回复：尊敬的投资者，您好，公司创新药项目QHRD106、QHRD107等均按计划有序推进临床试验，目前正处于与监管部门积极沟通申请下一阶段临床研究的过程中。股价波动受多重因素影响，公司将持续关注国家创新药政策导向，全力推进创新药研发进程。具体进展请关注公司后续公告，感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2569099812","isCrawlerRequest":true}